

Gain an Understanding of Immunogenicity and Challenges in Biologics Development at Immunogenicity 2015

Following on from the success of the Immunogenicity conference last year, SMi announces their 2nd Immunogenicity conference on 29 - 30 June 2015 in London, UK

LONDON, UNITED KINGDOM, April 30, 2015

[/EINPresswire.com/](http://EINPresswire.com/) -- With the increase in demand for biologics in the Pharmaceutical Industry its important medicines are assessed for immunogenicity and methods to induce tolerance. SMi is pleased to announce the Immunogenicity [conference](#), the programme will explore the latest updates on the prediction and reduction of immunogenicity, clinical results and interpretations and optimising bioassays. Through a series of interactive presentations, [workshop](#) led by selected case studies from leading drug development teams, bioanalytical experts, and academics, the programme aims to provide insight on developments necessary to deliver safe, efficacious large molecule drugs to improve the lives of patients.



Renowned industry expert David Wraith, Chief Scientific Officer and Founder from Apitope International NV will be speaking on day 1, his presentation will discuss how to switch off unwanted immune responses, focusing on the following topics; Immunogenicity is unavoidable e.g. enzyme replacement therapy; Immunological tolerance mechanisms control immune responses to self and foreign antigens; The mechanisms of tolerance induction are now being revealed: here we will discuss novel insights into tolerance induction with peptide antigens; Examples will be given from the fields of allergy, autoimmune disease and blood clotting disorders

Expert speaker panel for 2015 includes: Annie De Groot, CEO and CSO, EpiVax, Inc., Sandra Garcês, Rheumatologist Consultant and Researcher, Garcia de Orta's Hospital, Margareta Wikén, Bioanalytical Manager, Swedish Orphan Biovitrum, Morten Nielsen, Associate Professor, The Technical University of Denmark, Gerhard Niederfellner, Head of Tumour Cell Biology, Pharma Research & Early Development, Roche Innovation Center Penzberg, Chloé Ackaert, Postdoctoral

Researcher, Cellular and Molecular Immunology, Free University of Brussels and many more...

In addition to the event, there will be an interactive workshop taking place on the 1st July entitled: Tools for early immunogenicity risk assessment and reduction, hosted by Sofie Pattijn, CTO, ImmunXperts SA and Morten Nielsen, Associate Professor, Center for Biological Sequence Analysis, Technical University of Denmark

This workshop will give an overview of in silico and in vitro tools and technologies to assess and reduce immunogenicity at an early development stage. Next to the technical details and case studies, there will also be an overview of the benefits and limitations of the different tools and how to implement these into your drug development strategy.

A brochure with a full list of speakers and presentations is available to download [online](#). For further information or to book a place, visit Marriott Regents Park Hotel, London, UK www.immuno.co.uk/EIN

Delegate enquiries: Contact Frederick Agbolety on +44 (0)20 7827 6070 or email: fagbolety@smi-online.co.uk

Immunogenicity is proudly sponsored by: SQI Diagnostics

2nd Annual Immunogenicity conference
29th & 30th June 2015
Marriott Regents Park Hotel, London, UK
www.immuno.co.uk/EIN

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

sam mahoney
SMi Group Ltd
+442078276000
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/262884444>
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.